| Tysabri (natalizumab) / Biogen, Royalty |
2019-002566-13: Personalizing the treatment with natalizumab in patients with multiple sclerosis |
|
|
| Not yet recruiting | 4 | 300 | Europe | natalizumab, Solution for infusion, Tysabri | Amsterdam University Medical Center, Innovatiefonds Zorgverzekeraars, Stichting MS Research, de Hersenstichting | Relapsing remitting multiple sclerosis, Multiple sclerosis (MS), Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT04048577: A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab |
|
|
| Recruiting | 4 | 10 | US | Dosing Interruption of Natalizumab, Dosing Interruption of Tysabri | Berkovich, Regina MD, PhD Inc., Biogen, Cedars-Sinai Medical Center | Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | 11/21 | 12/21 | | |
NCT05532163: A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) |
|
|
| Terminated | 4 | 1 | Europe | Natalizumab, Tysabri, BG00002 | Biogen | Multiple Sclerosis, Relapsing-Remitting | 10/23 | 10/23 | | |
NCT04178005: Cladribine Tablets After Treatment With Natalizumab (CLADRINA) |
|
|
| Active, not recruiting | 4 | 40 | US | Cladribine, Mavenclad | University of Texas Southwestern Medical Center, EMD Serono | Multiple Sclerosis | 08/24 | 12/26 | | |
| Terminated | 4 | 1 | US | Natalizumab 300 MG in 15 ML Injection | Vanderbilt University Medical Center, Biogen | Multiple Sclerosis | 04/23 | 04/23 | | |
NOVA, NCT03689972 / 2018-002145-11: A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration |
|
|
| Completed | 3 | 585 | Europe, Canada, US, RoW | Natalizumab, BG00002 | Biogen | Multiple Sclerosis, Relapsing-Remitting | 01/23 | 07/23 | | |
NCT05265728: A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis |
|
|
| Terminated | 3 | 21 | Japan | Natalizumab, BG00002 | Biogen | Multiple Sclerosis, Relapsing-Remitting | 01/24 | 05/24 | | |
BEAT-MS, NCT04047628: Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis |
|
|
| Recruiting | 3 | 156 | US | Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Best Available Therapy (BAT), natalizumab (Tysabri®), alemtuzumab (Campath®, Lemtrada®), ocrelizumab (Ocrevus®), rituximab (Rituxan®), cladribine (Mavenclad®), ofatumumab (Kesimpta®), ublituximab (BRIUMVI™) | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Blood and Marrow Transplant Clinical Trials Network, PPD, Rho Federal Systems Division, Inc. | Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis | 10/26 | 10/29 | | |
NCT05418010: Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS) |
|
|
| Recruiting | 2 | 40 | Europe | Tysabri Injectable Product, Natalizumab, Placebo | Queen Mary University of London, Biogen, UCL Queen Square Institute of Neurology, Moorfields Eye Hospital NHS Foundation Trust, Barts & The London NHS Trust | Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination | 05/24 | 05/24 | | |
NCT05618301: Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) |
|
|
| Recruiting | 1 | 10 | US | Motixafortide, BL-8040, Natalizumab, Tysabri, Leukapheresis | Washington University School of Medicine, BioLineRx, Ltd., Biogen | Sickle Cell Disease | 12/25 | 12/25 | | |
| Completed | N/A | 39 | Europe | ocrelizumab, Ocrevus, natalizumab, Tysabri, ofatumumab, Kesimpta | Novartis Pharmaceuticals | Multiple Sclerosis | 04/23 | 04/23 | | |
| Completed | N/A | 60 | Europe | Natalizumab, Tysabri, BG00002 | Biogen | Relapsing Remitting Multiple Sclerosis | 10/23 | 10/23 | | |
| Completed | N/A | 318 | Europe | Natalizumab | Biogen | Relapsing-Remitting Multiple Sclerosis (RRMS) | 04/24 | 04/24 | | |
| Completed | N/A | 68 | Europe, RoW | Questionnaire | University Hospital, Bordeaux, Biogen | Multiple Sclerosis | 12/23 | 12/23 | | |
NCT03399981: Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries |
|
|
| Completed | N/A | 80327 | US | Tysabri, Natalizumab BG00002 | Biogen | Progressive Multifocal Leukoencephalopathy | 12/23 | 12/23 | | |
SATURATE-MS, NCT05701423: A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants |
|
|
| Terminated | N/A | 34 | Europe | Natalizumab, Tysabri | Biogen | Multiple Sclerosis | 07/24 | 07/24 | | |
NCT05925049: A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS) |
|
|
| Active, not recruiting | N/A | 400 | US | Natalizumab, Tysabri | Biogen | Multiple Sclerosis | 12/25 | 12/25 | | |
NCT05236777: TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants |
|
|
| Recruiting | N/A | 600 | RoW | Natalizumab, Tysabri | Biogen, ReMuS Registry | Multiple Sclerosis | 04/25 | 04/25 | | |
| Completed | N/A | 6620 | Europe, Canada, RoW | Tysabri, BG00002, natalizumab | Biogen | Relapsing-Remitting Multiple Sclerosis | 11/23 | 11/23 | | |
|
|
|
|
|
|
|
|
|
NCT05688436: A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate |
|
|
| Recruiting | N/A | 1178 | US | Diroximel Fumarate, VUMERITY, BIIB098, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Tysabri, BG00002, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod | Biogen | Multiple Sclerosis | 01/31 | 01/31 | | |
NCT05658497: Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) |
|
|
| Recruiting | N/A | 908 | Europe, US | Diroximel Fumarate, VUMERITY, BIIB098, Avonex, BG9418, interferon beta-1a, Tysabri, Natalizumab, BG00002, Dimethyl Fumarate, Tecfidera, DMF, BG00012 | Biogen | Multiple Sclerosis | 07/32 | 07/32 | | |